Printer Friendly

CLOZARIL THERAPY BENEFITS 43,000 PATIENTS NATIONWIDE

 SAN FRANCISCO, May 27 /PRNewswire/ -- Three years after its introduction, CLOZARIL(R) (clozapine), the only atypical antipsychotic medication available for the treatment of schizophrenia, continues to exceed clinical expectation by providing patients with significant improvement in both symptom control and quality of life, it was reported today by Gil Honigfeld, Ph.D., director of Scientific Affairs, Sandoz Pharmaceuticals Corporation, at a forum at the American Psychiatric Association's annual meeting.
 According to Dr. Honigfeld, the medical community has documented that CLOZARIL has enabled many patients who have responded poorly to standard antipsychotic therapy to achieve a level of recovery that allows for successful reintegration back into society.
 In his third annual update to the association, Dr. Honigfeld reported that more than 43,000 patients nationwide are currently benefiting from CLOZARIL therapy. "Clearly, patient access to CLOZARIL is increasing, but unfortunately, the rate of increase is not consistent nationally. This situation, while frustrating to advocates and professional alike, is a much more serious issue for patients who deserve quality care and the opportunity to live better and more productive lives," noted Honigfeld.
 Dr. Honigfeld also provided updates of potential therapeutic risks of CLOZARIL therapy. He noted that while agranulocytosis remains a clinical risk, the more than 18,000 physicians prescribing CLOZARIL have managed the risk with weekly blood monitoring and reporting that has resulted in an actual incidence of agranulocytosis of less than 1 percent in comparisons to the estimated one-to-two percent incidence that would occur without monitoring.
 "The good news for practitioners is that therapeutic approaches to schizophrenia that involve CLOZARIL(R) therapy provide patients with the optimal benefits available in symptom control and improved quality of life. What's more, the risk of therapy can be successfully managed with weekly monitoring by the physicians and pharmacists, thereby helping to ensure patient safety," concluded Dr. Honigfeld.
 Introduced in 1991, the atypical antipsychotic CLOZARIL is considered the first major breakthrough for schizophrenia in 40 years. CLOZARIL is indicted for patients with schizophrenia who have not achieved adequate response to standard neuroleptics or who experience intolerable side effects from traditional therapies.
 Weekly blood tests are required because CLOZARIL therapy is associated with an estimated one-to-two percent incidence of agranulocytosis, a potentially fatal condition resulting from a major decline in white blood cell count. Other potential side effects include seizure, drowsiness, transient tachycardia, hypotension, and fever.
 -0- 5/27/93
 /CONTACT: William O'Donnell, 201-503-7070, for Sandoz Pharmaceuticals Corporation,/


CO: Sandoz Pharmaceuticals Corporation ST: California IN: MTC SU:

TS-SM -- NY085 -- 3125 05/27/93 16:50 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 27, 1993
Words:421
Previous Article:DIAMOND FIELDS RESOURCES INC. CLOSES $5.7 MILLION PRIVATE PLACEMENT AND ANNOUNCES PROPERTY ACQUISITION
Next Article:SARASOTA CO. (FL) HOSP. DIST. $60 MIL BONDS 'A+/F-1' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
SANDOZ PHARMACEUTICALS SETTLES LITIGATION
DRUG LAWSUIT SETTLED; SCHIZOPHRENICS TO BENEFIT
SANDOZ PHARMACEUTICALS SETTLES LITIGATION
SANDOZ REPORTS NEW STUDY CONFIRMS BENEFITS OF CLOZARIL THERAPY AND MONITORING
MENTAL HEALTH PROFESSIONALS REPORT DRAMATIC PATIENT RECOVERY; CREATES REVOLUTION IN SCHIZOPHRENIA PATIENT CARE
CAREMARK ANNOUNCES AGREEMENT TO SELL CLOZARIL PATIENT MANAGEMENT BUSINESS TO HEALTH MANAGEMENT, INC.
Clozaril(R) (Clozapine) Reduces the Rate of Suicide in People With Schizophrenia, According to Study in the Journal Epidemiology
Unique Clozaril National Registry Paramount to Patient Safety
FDA Approves Clozaril(R) to Reduce the Risk of Suicidal Behavior; - Drug is First Ever With Indication -.
FDA Committee Recommends Approval for Clozaril(R) to Treat Suicidal Behavior.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters